Transforming growth factor-beta (TGF-B) plays an important role in embryo implantation; however, TGF-B requires liberation from its inactive latent forms (i.e., large latent TGF-B complex [LLC] and small latent TGF-B complex [SLC]) to its biologically active (i.e., monomer or dimer) forms in order to act on its receptors (TGF-BRs), which in turn activate SMAD2/3. Activation of TGF-B1 from its latent complexes in the uterus is not yet deciphered. We investigated uterine latent TGF-B1 complex and its biologically active form during implantation, decidualization, and delayed implantation. Our study, utilizing nonreducing SDS-PAGE followed by Western blotting and immunoblotting with TGF-B1, LTBP1, and latency-associated peptide, showed the presence of LLC and SLC in the uterine extracellular matrix and plasma membranous protein fraction during stages of the implantation period. A biologically active form of TGF-B1 (;17-kDa monomer) was highly elevated in the uterine plasma membranous compartment at the peri-implantation stage (implantation and nonimplantation sites). Administration of hydroxychloroquine (an inhibitor of pro-TGF-B processing) at the preimplantation stage was able to block the liberation of biologically active TGF-B1 from its latent complex at the postimplantation stage; as a consequence, the number of implantation sites was reduced at Day 5 (1000 h), as was the number of fetuses at Day 13. The inhibition of TGF-B1 showed reduced levels of phosphorylated SMAD3. Further, the delayedimplantation mouse model showed progesterone and estradiol coordination to release the active TGF-B1 form from its latent complex in the receptive endometrium. This study demonstrates the importance of liberation of biologically active TGF-B1 during the implantation period and its regulation by estradiol. decidualization, delayed implantation, embryo implantation, latent TGF-B1 complex, ovarian steroids, TGF-B1 activation
INTRODUCTION
The transforming growth factor-beta (TGF-B) is a cytokine that has a wide range of functions. TGF-B acts through its membrane receptors, called TGF-B receptors, to activate the SMAD pathway by triggering phosphorylation of SMAD2/3 complex (activation). The activated pSMAD2/3 migrates to the nucleus and transcribes TGF-B-responsive genes [1] such as integrins [2] , fibronectin [3] , collagens [4] , and plasminogen activator inhibitor1 [5] . Expression of TGF-B has been discovered in reproductive tissues as well [1] . There are three known isoforms of TGF-B: TGF-B1, -B2, and -B3. Of these, TGF-B1-and TGF-B2-null mice have demonstrated an extended ovarian cycle and irregular ovulation (40% reduction in ovulation) [6] , which affects fertility; however, uterine tissue-specific deletion of TGF-B1 has not yet been studied.
The TGF-B1 is expressed in the conceptus and maternal interface, secondary decidual zone, and developing endothelial cells in the decidua [7] . Uterine decidua-derived TGF-B1 promotes vasculature maturation [8] and, hence, coordinates the process of embryo implantation. Furthermore, TGF-B1 is secreted by endometrial epithelial cells in response to progesterone, which acts on adjacent uterine stromal cells to activate SMAD signaling [9] . The activated SMAD leads to decidualization, which is a crucial step for embryo implantation [10, 11] .
In most of the cells in which it is expressed, TGF-B1 is secreted in the inactive, latent form in association with latent TGF-B-associated peptide (LAP), latent TGF-B1 binding proteins (LTBP-1), and TGF-B1 dimer [12] . TGF-B1 is synthesized as a pre-pro-TGF-B1 polypeptide (50) (51) (52) (53) (54) (55) (56) (57) (58) (59) (60) that comprises the signaling peptide (pre; residues 1-29), the pro region (residues , and the mature TGF-B1 moiety (residues 279-390) [13] . TGF-B1 is generally produced as a large latent complex (LLC) in which LAP-TGF-B1 (small latent complex [SLC] ) is bound to another high-molecularweight protein called LTBP [14, 15] , which gives rise to a pro-TGF-B1-LAP and LTBP complex of ;220 to ;235 kDa in size [16] . Inactive, latent TGF-B1 can exist in the cell either as an SLC or LLC [14] . The SLC can be visualized on the nonreducing Western blot at ;75 [17] , 80, 84, 90, or 100 kDa [18, 19] . The LTBP targets the latent TGF-B1 to the extracellular matrix (ECM) [20] , where it is stored as a reservoir and serves as a source of TGF-B1 availability [21] . LTBP-1 has been reported in various sizes: 125-210 kDa in the platelets and fibroblast [22] , though its 100-to 180-kDa size has also been noted [23] .
The latency of TGF-B1 is dependent on the presence of LAP [24] . LAP is a 37-to 40-kDa protein associated with the TGF-B1 homodimer (25 kDa), whereas TGF-B1 monomeric form is ;13 kDa [15] or ;17 kDa [25] . LTBP is required for the correct folding and secretion of TGF-B1 [26] . Evidence suggests that various agents like thrombospondin (TSP) and integrins B1, B6, and B8 as well as mobilization of latent TGF-B1 from the ECM to the plasma membrane during its activation process [27] can activate TGF-B on the cell surface (plasma membrane) [14] . The liberated or latent complex-free TGF-B1 can bind to its receptors on the plasma membrane, which propagates its signal through SMAD2/3 phosphorylation.
TGF-B1 is associated with embryo implantation and decidualization [7] [8] [9] . TGF-B1 is known to be secreted in the inactive, latent form, but no detailed study exists on the state of TGF-B1 complexes in the uterus during embryo implantation, barring the recent study in porcine implantation, which rests solely on immuno-cytochemical analysis [28] . But accurate discrimination of latent versus active TGF-B1 is not possible by mere immunohistochemical detection. In this study, we have evaluated the expression of latent TGF-B1 complex in the ECM and of the biologically active form of TGF-B1 in the plasma membrane of uterus during the implantation period. Additionally, we attempted to see how ovarian hormones regulate the liberation of biologically active TGF-B1 from its inactive/latent complex.
MATERIALS AND METHODS

Reagents
Anti-TGF-B1 (sc-146), LAP (sc-34830), LTBP-1 (sc-28133), Protein AAgarose (sc-2001), and Collagen a1 Type I (sc-8784) were purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA). LTBP-1 antibody (ab78294) was purchased from Abcam (Cambridge, MA). Anti-b-actin (A2668), rabbitanti-goat IgG horseradish peroxidase (HRP)-conjugated antibody (A5420), progesterone, 17b-estradiol (estradiol), and hydroxychloroquine were purchased from Sigma-Aldrich Inc. (St. Louis, MO). Goat anti-rabbit IgG conjugated antibody with HRP (Genei, lot 032071), Immobilon-P polyvinylidene fluoride membrane (0.45 lm), and enhanced chemiluminescence reagent kits were from Merck-Millipore (Darmstadt, Germany). The anti-SMAD2/3 (8685S) and anti-phospho-SMAD3 (Ser423/425; C25A9) were from Cell Signaling Technology Inc. (Danvers, MA). Nonfat milk (170-6404), precision protein marker (161-0373), and protein assay kit (500-0111) were purchased from Bio-Rad (Hercules, CA).
Experimental Animals
Mature female mice (Mus musculus; Swiss albino strain, 3 mo old) were used in this study. All the animal protocols were approved by the Institutional Animal Ethical Committee at CSIR-CDRI, Lucknow, and RGCB, Trivandrum, India. Stages of the estrous cycle were verified by following the previously described method [29, 30] .
For studies on pregnant mice, sexually mature, virgin, female mice with regular estrous cycle were housed with males (3-4 mo old) of proven fertility. Mating was confirmed by the presence of a whitish vaginal plug the following morning, which was designated as Day 1 of pregnancy. Uterine tissues were obtained from these animals during different days of the implantation period, i.e., Day 4 (1000 h) (preimplantation), Day 4 (1600 h) (late preimplantation), Day 5 (0500 h) (peri-implantation) and Day 5 (1000 h) (postimplantation). These stages were designated based on the stage of the embryo, i.e., morula, early blastocyst, hatched blastocyst, and implanted blastocyst. The excised uterine horn was flushed gently through the oviductal end with 1.0 ml sterile PBS to obtain the embryo and verify the stage. Evans Blue dye (0.1%) was administered by tail vein injections before euthanizing the animals during Day 5 (0500 h) or Day 5 (1000 h) stages. Implantation and nonimplantation sites of blastocysts in the uterus were visualized by injecting 50 ll of 0.1% Evans Blue as previously described [31] . The clearly blue-colored implantation and faintly colored nonimplantation region were separated and processed for the extraction of protein. These uteri from different mice of the same stage were processed individually for the ECM (n ¼ 3). Crude plasma membrane (cytosol þ plasma membrane) protein (n ¼ 5) extract was prepared from separate animal uteri.
Delayed-Implantation Mouse Model
In a delayed embryo-implantation model, pregnant female mice were bilaterally ovariectomized at 1600 h on Day 3 of pregnancy under ketamine (30 mg/kg body weight) and xylazine (4 mg/kg body weight) anesthesia. Animals of all the groups (n ¼ 5) received progesterone (1.0 mg/25 g body weight) dissolved in corn oil at 1700 h from Day 3 to Day 7 of pregnancy. In one group, animals (n ¼ 5) received estradiol in 50 ll corn oil (25 ng/25 g body weight) along with the dosage of progesterone on Day 7 of pregnancy [32] . Steroids (50 ll per animal) were delivered through s.c. injections at 1700 h for 5 consecutive days. The female mice were euthanized at 1000 h on Day 8 of pregnancy, and embryos were verified as previously described [33] . The delayed or activated implantation was confirmed by microscopic observation of the metabolically dormant or activated blastocyst in the uterine flush as described in earlier studies [34] [35] [36] . The progesterone keeps the blastocyst dormant, so the inner cellular mass (ICM) is not well developed. However, when the estradiol is supplied in the background of the progesterone, the blastocyst becomes active, so the ICM is more prominent and distinct in appearance [34] [35] [36] . The excised uteri were cleared of adherent fat by washing thoroughly in the PBS and were then processed for membrane protein extraction.
Inhibition of Active TGF-B Liberation by Hydroxychloroquine During Embryo Implantation
The pregnant female mice underwent mini-laparotomy via bilateral incision on Day 4 (1000 h) as previously described [37, 38] . The utero-tubal junction was held gently and, with the aid of a microsyringe, 10 lM hydroxychloroquine in 5 ll distilled water was injected into one of the uterine horns, while the other horn received 5 ll of distilled water as a sham/vehicle control (n ¼ 5 per group). These operated females were monitored till Day 13 [39] . On Day 13, the treated animals were euthanized, and the number of implanted embryos was recorded (n ¼ 5 per group). Additionally, we determined the embryo development status, number of embryo implantation sites at Day 5 (1000 h), and decidualization at Day 7 in a separate set of the above drug-treated groups [40] . Implantation sites in the uterus were visualized as described previously [31] . The Evans Blue-colored implantation and non/faint-colored nonimplantation region were separated and processed for the extraction of protein.
Experimental Decidualization Induction in Nonpregnant Mice
We induced experimental decidualization in pseudopregnant female mice (n ¼ 5), which were mated with vasectomized male mice. Briefly, the male mice were vasectomized as described previously [41] . The vasectomized male mice were allowed to rest for 1 wk. Thereafter, the sexually mature females were caged with these vasectomized males to achieve pseudopregnancy, which was confirmed by observation of the whitish vaginal plug on the next day. The experimental decidualization was induced in the pseudopregnant female mice at Day 3 (1600 h) by the intrauterine infusion of 10 ll corn oil in one uterine horn, while the contralateral uninjected horn served as a nondecidualized control. The animals were euthanized after 72 h to collect the decidualized and nondecidualized uterine tissue and were processed separately [42] .
Extraction of Uterine ECM Proteins
ECM-associated proteins were isolated as previously described [43] . The whole uterine tissue was homogenized in ice-cold Tris-buffered saline containing 1 mM PMSF, 10 lg/ml leupeptin, and 0.7 g/ml pepstatin A at a 10:1 vol/wt ratio. Thereafter, centrifugation at 15 000 3 g in a tabletop centrifuge (model no. 5804 R, Rotor no. F45-30-11; Eppendorf, Hamburg, Germany) for 30 min at 48C was done, and the resultant pellet was resuspended in an extraction buffer (50 mM Tris-HCl [pH 7.5], 150 mM NaCl, 50 mM noctylglucoside, 2 mM MgCl 2 , 1 lg/ml PMSF, 10 lg/ml leupeptin, and 0.7 lg/ ml pepstatin A). After a 10-min extraction at 48C, samples were again centrifuged at 15 000 3 g for 30 min at 48C to remove debris. Supernatant was designated as the ECM protein fraction and was stored at À808C until use.
Preparation of Membranous Protein Extract from Uterus
Implantation and nonimplantation sites of the uterus at different stages were processed separately. Uterine tissue was minced properly in buffer containing 100 mM KCl, 3 mM NaCl, 3.5 mM MgCl 2, 10 mM PIPES, 1.5 mM ethylene glycol tetraacetic acid, 1 mM PMSF, 50 lg/ml leupeptin, 25 lg/ml pepstatin, and 25 lg/ml aprotinin (pH 7.4) as described previously [44, 45] . Then the tissue was homogenized and centrifuged (48C) at 200 3 g to separate unbroken cells and then at 1470 3 g for 10 min to separate nuclei. The post-nuclear supernatant was again centrifuged (48C) at 12 000 3 g for 10 min to collect supernatant as a crude membranous protein extract. The crude plasma membranous extract was made because of nonfractionability into cytosol and plasma membrane compartments.
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Immunoprecipitation
This protocol was adapted from a previously described method [46] in which protein extracts (crude plasma membranous fraction) were precleared with Protein A-Agarose. The pre-cleared protein extract was incubated with anti-TGF-B1 (5 lg/10 ll) in 100 lg protein extract (4:1 ratio) overnight at 48C [46] . The Protein A-Agarose was washed in PBS, and 50% slurry of Protein-AAgarose was prepared in the membrane protein isolation buffers. The immune complexes were captured by addition of Protein-A-Agarose (;10 lg/10 ll) for 1 h at 48C. Thereafter, protein (immunoprecipitation [IP]) samples were resolved by 12% SDS-PAGE and subjected to Western blotting.
SDS-PAGE and Western Blotting
The whole uterine ECM and crude plasma membrane protein concentrations from implantation and nonimplantation sites were estimated by the BioRad protein assay kit. Proteins were denatured with Laemmli buffer [47] containing b-mercaptoethanol. For native SDS-PAGE, proteins were not denatured (i.e., without b-mercaptoethanol and heating). For immunoblotting, a uterine tissue protein fraction (20 lg) or immunoprecipitated samples were separated on a 12% SDS-PAGE, while denatured protein was run on a 10% SDS-PAGE at a constant 100 V using a Tetra Protean Cell vertical electrophoretic system (Bio-Rad) and electro-blotted onto polyvinylidene fluoride membrane using a transfer buffer described in Towbin et al. [48] .
Immunoblotting
The blotted membranes were incubated with 5% nonfat milk blocker for 2 h at room temperature. After blocking, the membranes were incubated overnight at 48C with the respective primary antibody (anti-TGF-B1, LAP, LTBP-1, SMAD2/3, pSMAD3, or b-actin). Later, membranes (blot) were probed with a secondary antibody that was conjugated with HRP in 1:3000 dilution. PBS containing 0.1% Tween-20 (PBS-T; 10 mM; pH 7.4) was used throughout the procedure, and each step was followed by three washings with PBS-T. The antibody incubation was done in 1% nonfat milk blocker. The TGF-B1 and LAP antibodies were used in 1:500 dilution, and the antibodies for LTBP-1, SMAD2/3, pSMAD3, and Collagen a1 Type I were used in 1:1000 dilution. The housekeeping gene/gel-loading internal control, anti-b-actin, was in 1:4000 dilution. Protein bands were visualized by Merck-Millipore enhanced chemiluminescence kit. Immunoblots were imaged through ImageQuant LAS 4000 gel documentation system (GE Life Science, Pittsburgh, PA), and immunopositive bands were quantified by TotalLab Quant1D software version 5.0 (Nonlinear Dynamics Ltd., Newcastle upon Tyne, U.K.).
Histology
Uterine tissues were excised out and fixed in 4% paraformaldehyde, dehydrated in ethanol gradients and xylene, and finally embedded in paraffinwax blocks. The tissue blocks were sectioned (thickness, 6 lm) and stained with hematoxylin and eosin as described elsewhere [40] .
Statistical Analysis
Each experiment was performed with five separate animals (n ¼ 5) as a replicate except for ECM-related experiments (n ¼ 3); experiments were repeated a minimum of three times. Protein band intensities were averaged, and the SEM was calculated; both are presented in the histograms. The Student ttest was used to compare data between the groups, and significance was expressed as P , 0.05. Error bars in the figures (histogram) represent SEMs. Each replicate of TGF-B1, SMAD2/3, pSMAD3, LAP, and LTBP-1 blot values was normalized with the corresponding b-actin value.
RESULTS
TGF-B1 Latent Complex and Associated Proteins in the ECM Act as Possible Reservoirs During the Implantation Period
The association of the latent TGF-B1 complex with the ECM acts as a regulatory mechanism for the availability of active TGF-B1 [23] . Therefore, we sought to determine the existence of various latent TGF-B1 complexes, i.e., the LLC (;220 kDa) and SLC (;75 kDa), in the uterine ECM during the implantation period (n ¼ 3 per stage per group). We utilized already-validated anti-TGF-B1 in our experiments [49, 50] . To investigate the latent/inactive and the biologically active form of TGF-B1 (;25-kDa dimer and ;17-kDa monomer, respectively), a nonreducing SDS-PAGE followed by Western blotting and immunoblotting was performed. The ECM largely consists of Collagen a1 type I, and we used it as an ECM compartment marker. Because the expression of Collagen a1 type I was found to be oscillating, b-actin, which was found to be unchanged in the ECM protein fraction, was used as a loading control.
The anti-TGF-B1 detected LLC (;220 kDa) and SLC (;74 kDa) as reported previously [19, 26, 51, 52] in the uterine ECM protein fraction (Fig. 1A) . LLC was present at all stages of embryo implantation (Fig. 1A) . The SLC protein level did not show a detectable amount at Day 4 (1000 h), whereas protein levels were moderate at the rest of the stages (Fig. 1A) . The ECM fraction did not show any free form (biologically active) of TGF-B1 in either a monomer (;17 kDa) or dimer (;25 kDa) state. These observations suggest that activation of TGF-B1 is not taking place in the ECM compartment of the uterus despite the availability of LLC and SLC.
The TGF-B1 associates with the LAP and LTBP-1, giving rise to latency for the TGF-B1 [15] . Therefore, we examined LAP protein complexes with TGF-B1 and LTBP-1 in the uterine ECM protein fraction. LAP protein was detected as a complex at ;220 kDa and ;75 kDa, which corresponds to LLC and SLC (Fig. 1B) , respectively. There was no change observed in these TGF-B1 latent protein complexes detected by the anti-LAP, but this strongly confirms its association with TGF-B1 and LTBP-1 (Fig. 1B) .
The LTBP-1-probed immunoblot also recognized LLC at ;220 kDa, with an additional band of LTBP-1 at ;100 kDa (Fig. 1C) . The LLC recognition by the anti-LTBP1 confirmed its association with TGF-B1. The LTBP-1 did not show any significant changes in the stage of the implantation period, suggesting a latent TGF-B1 reservoir in the uterine ECM compartment.
Liberation of TGF-B1 from Its Latent Complex During the Implantation Period
A previous study showed expression levels of TGF-B1 in the uterus during embryo implantation [53] . Herein, we detected and monitored the expression level of biologically active TGF-B1 in the uterus during the implantation period. The TGF-B1 activation or liberation from its latent complex takes place at the cell surface [27] ; therefore, we performed native/nonreducing SDS-PAGE and immunoblotting with TGF-B1 on the uterine crude plasma membrane protein fraction that had been collected at different stages of embryo implantation (n ¼ 5 per stage per group). We separated implantation and nonimplantation sites of the uterus to study the release of TGF-B1 in a site-specific manner. Because of the very small amount of implantation and nonimplantation tissue, it was difficult to obtain a sufficient amount of plasma membrane protein fraction; therefore, we studied it along with the cytosolic fraction and denoted both as the crude plasma membrane fraction.
Anti-TGF-B1 identified LLC (;220 kDa), SLC (;75 kDa), and active ;17-kDa immunopositive proteins bands on the blot (Fig. 2A) . The LLC expression level was noted to be high in all the stages of embryo implantation studied ( Fig. 2A) . The LTBP-1-devoid TGF-B1 latent complex SLC (;75 kDa) was faint and just detectable during Day 4 (1000 h) and Day 4 (1600 h) (Fig. 2, A and B) . The subsequent stage, Day 5 (0500 h) (implantation and nonimplantation sites), showed elevation LIBERATION OF TGF-B1 FROM LATENT COMPLEX IN UTERUS in SLC protein levels (P , 0.01; Fig. 2, A and B) . Implantation sites of Day 5 (0500 h) represented higher levels of SLC than those of nonimplantation sites (P , 0.02; Fig. 2, A and B) . A decrease in the expression level of SLC was noticed at Day 5 (1000 h) (P , 0.01; Fig. 2, A and B) . Another latent form of TGF-B1, pro-TGF-B1, was also detected and exhibited increased expression at the implantation sites of Day 5 (0500 h)-stage uterus in comparison to that at the Day 4 (1000 h) (P , 0.004) stage. Pro-TGF-B1 expression was decreased at Day 5 (1000 h) (P , 0.01) in the implantation sites (Fig. 2, A and  C) . A similar expression pattern of pro-TGF-B1 was noticed in the nonimplantation sites of the Day 5 (0500 h) and Day 5 (1000 h) stages (Fig. 2, A and C) .
Anti-TGF-B1 exhibited a biologically active or mature TGF-B1 monomer form (;17 kDa), and its expression was low at the Day 4 (1000 h) and Day 4 (1600 h) stages. Elevation of TGF-B1 monomer expression was observed in the implantation and nonimplantation sites of Day 5 (0500 h) (P , 0.008; Fig. 2, A and D) . As the stage advanced to Day 5 (1000 h), the level of TGF-B1 monomer decreased in the implantation (P , 0.009) and nonimplantation sites (P , 0.01; Fig. 2, A and D) . These observations suggest that a more 
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biologically active TGF-B1 form is available by liberating it from its latent complex during embryo implantation and that the release of TGF-B1 from the latent complex is happening at Day 5 (0500 h) (Fig. 2, A and D) .
LAP associates with the TGF-B1 dimer and gives rise to SLC, which later forms a complex with LTBP-1 as an LLC. The LAP antibody showed LLC (;220 kDa) and SLC (;75 kDa) on the immunoblot (Fig. 2E) . The LLC showed a high expression level throughout the stages of implantation (Fig.  2E) . The SLC was present in all the implantation stages studied; however, it was expressed in moderate levels at the Day 4 (1000 h) and Day 4 (1600 h) stages, then showed an increase at the Day 5 (0500 h) implantation sites (P , 0.04; Fig. 2 , E and F), followed by a decline at the Day 5 (1000 h) stage (implantation and nonimplantation sites; P , 0.03; Fig.  2, E and F) . A pro-TGF-B1 complex-associated LAP showed relatively high expression at implantation sites of Day 5 (0500 h) that receded at Day 5 (1000 h) (Fig. 2, E and G) . This indicates release of SLC from LLC, which further gives rise to the active TGF-B1 monomer (;17 kDa) at Day 5 (0500 h) (Fig. 2, E and G) .
LTBP-1 showed high expression in the stages studied (Fig.  3, A and B) . The free form of LTBP-1 was also observed at ;100 kDa, and there were no significance differences in the expression levels among the stages studied (Fig. 3, A and B) .
TGF-B1-LAP-LTBP-1 Interaction Confirmation Study
To verify that anti-TGF-B1 and LAP recognized LLC and SLC, we performed an IP study on the uterine crude plasma membranous protein extract from each studied implantation stage. The TGF-B1 IP blot was probed with anti-LTBP-1, which showed the presence of LTBP-1 in all the stages of implantation studied (Fig. 4A) . Further, we performed 
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immunoblotting with anti-LAP on the TGF-B1 IP blot, and LAP was seen in all the stages studied (Fig. 4B) , which strengthens our finding that the LTBP-1 and LAP associate in the TGF-B1 latent complex in the uterus during embryo implantation. The TGF-B1 presence in its IP was confirmed by immunoblotting (Fig. 4C) .
Effect of Inhibition of TGF-B1 Liberation on Embryo Implantation
Lysosomotropic drug hydroxychloroquine is an inhibitor of the pro-TGF-B1 activation process [54] . To investigate the functional role of liberation of active TGF-B1 from its latent complex during embryo implantation, we delivered hydroxychloroquine in the uterine lumen during the Day 4 (1000 h) stage of embryo implantation. Administration of hydroxychloroquine resulted in fewer implantation sites (P , 0.0002) at Day 5 (1000 h) (n ¼ 5) compared with the sham/vehicletreated uterine group (n ¼ 5; Fig. 5, A and B ). There were fewer recovered blastocysts/embryos after hydroxychloroquine treatment (P , 0.002) than were recovered after sham/vehicle treatment (Fig. 5, C and D) . The number of embryos collected from the uterine flushes was equivalent to the number of embryos of implantation sites observed. Thereafter, we determined the effect of pro-TGF-B1 inhibition on embryo development during the Day 5 (1000 h) stage. Our results showed loss in embryo morphology in the hydroxychloroquine-treated group, whereas the control embryo/blastocyst had clearly distinguishable ICM, blastocoels, and trophoblasts (Fig.   5C ). The hydroxychloroquine-treated uterine horn had fewer embryos than that of control (Fig. 5D ).
Later on, we determined the effect of liberation of TGF-B1 on pregnancy at Day 13. Our results showed that inhibition of pregnancy led to a reduction (27%) in the number of fetuses at Day 13 (P , 0.009) in the hydroxychloroquine-treated (10 lM) uterine horn (n ¼ 5 per group; Fig. 5 , E and F) compared with the control. This implies that loss of embryos due to inhibition of liberation of biologically active TGF-B during embryo implantation consequenctly affected the development of blastocyst and endometrium receptivity that leads to the reduction in fetus numbers at Day 13 of pregnancy.
Furthermore, to validate the effect of inhibition of pro-TGF-B1 processing or liberation at Day 5 (1000 h), we performed immunoblotting with TGF-B1. We dissected out implantation and nonimplantation sites of Day 5 (1000 h) uteri to acquire detailed information about TGF-B1 liberation in a site-specific manner. The proteins were resolved under nondenatured/ reducing SDS-PAGE followed by immunoblotting with anti-TGF-B1. Expression levels of LLC were observed to be very high in the nonimplantation and implantation sites of sham-(n ¼ 5) and hydroxychloroquine-treated (n ¼ 5) uterus (Fig. 6, A  and B) . TGF-B1 latent complex lacking LTBP-1 (SLC) was seen in low levels in the implantation and nonimplantation sites of the hydroxychloroquine-treated uterus when compared with the sham/vehicle (Fig. 6, A and B) . The pro-TGF-B1 form was noticeably higher in implantation sites of hydroxychloroquine and sham groups than in those of the respective nonimplantation sites (P , 0.001, P , 0.003, respectively; Fig.   FIG. 4 . TGF-B1, LTBP-1, and LAP interaction study. A) LTBP-1 was immunoprecipitated with TGF-B1 from the stage of embryo implantation. B) Similarly, LAP was also immunoprecipitated with TGF-B1. C) TGF-B1 presence was confirmed by immunoblotting in the IP of TGF-B1.
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6, A and C). The hydroxychloroquine-treated group showed a significant reduction in the mature or biologically active form of TGF-B1 at the implantation sites compared with the sham/ vehicle group (P , 0.02; Fig. 6, A and D) . The nonimplantation sites of sham-and hydroxychloroquine-treated groups were devoid of mature TGF-B1 (Fig. 6, A and D) .
The inhibition of TGF-B1 processing by hydroxychloroquine has already been reported [54] , so our experimental setup does not need any further validation. We examined the activity of TGF-B1 after hydroxychloroquine treatment by analyzing the phosphorylation levels of the TGF-B1 downstream gene, SMAD3. The TGF-B receptor is activated by binding of TGF-B1, which in turn triggers SMAD3 phosphorylation [55, 56] , and the activated SMAD3 transcribes the TGF-B1-responsive genes [57] . First, we determined the relative expression levels of total SMAD2/3 in the implantation and nonimplantation sites of hydroxychloroquine-(n ¼ 5) and sham-treated groups (n ¼ 5; Fig. 6, E and F) . Total SMAD2/3 was found to be MAURYA ET AL. reduced in the implantation and nonimplantation sites of the hydroxychloroquine group compared with the sham/vehicle group (P , 0.005, P , 0.001, respectively; Fig. 6, E and F) . In the implantation sites of the hydroxychloroquine-treated uterine group, along with the decrease in active TGF-B1 level, there was a significant drop in the expression level of phosphorylated SMAD3 when compared to the sham/vehicle uterine group (P , 0.006; Fig. 6, G and H) . Further, the nonimplantation site-specific pSMAD3 was reduced almost 3-fold (P , 0.0003) in the hydroxychloroquine group compared with that of the sham group (Fig. 6, G and H) .
Liberation of TGF-B1 from Its Latent Complex During Decidualization
Earlier reports have described the requirements for decidualization of TGF-B [8, 9, 58] , where TGF-B is secreted by endometrial epithelial cells through the action of progesterone; this secreted TGF-B acts on the stromal cells [9] . To identify the relation of active TGF-B1 release (activation) with decidualization, we examined the expression of biologically active TGF-B1 in the uterus in response to experimentally induced decidualization.
On a nonreducing SDS-PAGE blot, anti-TGF-B1 showed classical TGF-B1 complex, i.e., LLC, SLC, and mature or biologically active TGF-B1, which is visible in Figure 7A . The LLC protein expression was relatively high in both the decidualized (n ¼ 5) and nondecidualized (n ¼ 5) groups (Fig. 7A) . LTBP-1 lacking TGF-B1 latent complex exhibited SLC (;75 kDa) in both groups (Fig. 7, A and B) . However, the crude plasma membrane protein fraction from decidualized uterine tissue depicted a higher level of SLC than the nondecidualized or control group (P , 0.03; Fig. 7, A and  B) . Additionally, pro-TGF-B1 was also noticed in both groups, though it was higher in the decidualized group than the nondecidualized group (P , 0.003; Fig. 7, A and B) . The biologically active or mature form of TGF-B1 monomer was detected at ;17 kDa and was drastically enhanced in the decidualized uterine group (P , 0.05; Fig. 7, A and C) .
Further, we studied the association of LAP with the latent TGF-B1 complex in the decidualized uterus. The anti-LAP detected the predicted LLC, SLC, and additional pro-TGF-B1 (Fig. 7D) . LLC was expressed in both the groups (Fig. 7, D and E). The expression level of SLC was higher in the decidualized uterine tissue (Fig. 7, D and E) than in the control group (P , 0.01). The anti-LAP also detected pro-TGF-B1, which was found to be elevated in the decidualized uterus in comparison to the nondecidualized or control group (P , 0.01; Fig. 7, D and E).
The SMAD3 is required for the decidualization, and it is activated by TGF-B1 signaling-dependent phosphorylation [9, 59] . Because we found increased levels of the biologically active form of TGF-B1 in the decidualized uteri (Fig.7, A and  C) , we looked for the phosphorylated SMAD3 (Fig. 8, A-D ). We first determined the level of SMAD2/3 in the decidualized (n ¼ 5) and nondecidualized uterine tissue groups (n ¼ 5; Fig. 8,  A and B) . The expression level of SMAD3 is augmented in the decidualized uterine tissue group in comparison to the nondecidualized group (P , 0.03; Fig. 8, A and B) . Similarly, the expression level of the active (phosphorylated) form of SMAD3 (pSMAD3) was ;2-fold higher in the decidualized group when compared to the control or undecidualized group (P , 0.007; Fig. 8, C and D) .
Furthermore, we examined the effect of hydroxychloroquine on uterine histopathology at the implantation and nonimplantation sites on Day 7 (Fig. 9) . The uterine tissue did not show cell proliferation in the nonimplantation sites to the same degree as was found in the implantation area of the shamtreated group due to lack of decidualization. The lumen was wide open in the nonimplantation sites, whereas closure of the lumen was observed at the implantation sites in the shamtreated group (Fig. 9, A and B) . The treatment with hydroxychloroquine resulted in less-proliferative tissue, which was small in size (section area) compared to that of the shamtreated implantation sites (Fig. 9, A and C) . This indicates inhibition of endometrium growth/proliferation in response to hydroxychloroquine-impaired decidualization.
Analysis of Liberation of TGF-B1 in Response to Ovarian Steroids Using a Delayed-Implantation Mouse Model
Progesterone has been reported to stimulate TGF-B1 expression [9] , but there is no report describing the role of ovarian steroids in the TGF-B1 liberation process. To determine this, we studied the liberation of TGF-B1 in response to ovarian steroids by using a delayed-implantation mouse model. Herein, we demonstrate the presence of LLC, SLC, and pro-TGF-B1 complexes in progesterone (n ¼ 5) and progesterone þ estradiol groups (n ¼ 5; Fig. 10A ) during delayed embryo implantation. LLC was present in higher levels in both of the groups; however, SLC showed a 60% increase in expression when estradiol was supplemented with progesterone compared with that of the progesterone alone group (P , 0.007; Fig. 10, A and B) . The pro-TGF-B1 expression remained unchanged in the progesterone and progesterone þ estradiol groups. The mature form of TGF-B1 was present as a monomer form (;17 kDa) in both the groups (Fig. 10, A and  C) , but no homodimer of the TGF-B1 was observed. The progesterone group showed a moderate release of the biologically active TGF-B1, which was enhanced (P , 0.005) about 2-fold upon addition of estradiol in the progesterone-primed uterus (Fig. 10, A and C) . This confirms progesterone-dependent release of TGF-B1 in the uterus, with estradiol enhancing the effects during the embryo-implantation process.
The anti-LAP detected the LLC, SLC, and pro-TGF-B1 at ;220, ;75, and ;50 kDa, respectively (Fig. 10D) . LLC and pro-TGF-B1 showed no significant change in expression level in the progesterone alone and progesterone þ estradiol groups (Fig. 10, D and E) . However, SLC was enhanced by estradiol in the background of progesterone (P , 0.0001; Fig. 10, D and E). LLC and SLC detection by the LAP and TGF-B1 antibodies suggests their association in these complexes and regulation by the estradiol hormone.
DISCUSSION
It is well established that TGF-B1 acquires biological activity after release from its latent (LLC and SLC) or inactive complex [14] . TGF-B1 has been reported to be up-regulated during pregnancy in the uterus [60] , but there is no detailed study showing the mechanism of TGF-B1 activation in the uterus during embryo implantation.
Our study revealed that TGF-B1 and LAP form critical components of the LLC and SLC, as they are present throughout the stages of embryo implantation on the uterine ECM. The LLC and SLC help to sequester TGF-B1 on the ECM, as no biologically functional TGF-B1 (;25 kDa or ;17 kDa) was seen on the uterine ECM. Interestingly, that there was no change in LTBP1 expression level indicates that it is dispensable during embryo implantation in the TGF-B1 signaling. Biologically active TGF-B1 (;17 kDa) was highest in the uterine plasma membranous compartment of embryo implantation sites at the Day 5 (0500 h) stage, and accordingly, LAP-positive LLC was also present in the stages of embryo implantation, thereby suggesting that TGF-B1 along with LAP is actively recruited onto the plasma membrane so as to increase bioavailability of TGF-B1 by conversion into a biologically active form. Expression of SLC and pro-TGF-B1 was many fold higher at Day 5 (0500 h) and was more predominant at implantation sites. This suggests that dissociation of LAP and TGF-B1 from SLC gives rise to biologically active TGF-B1 (;17 kDa) for embryo implantation in the periimplantation stage, thereby liberating the TGF-B1 on the uterine plasma membrane compartment during the implantation period. The liberated, biologically active form of TGF-B1 might be acting upon its receptors to transduce the signaling.
TGF-B1 is secreted in association with LTBP-1 as an LLC [23] ; therefore, we wanted to confirm this association in the uterus during embryo implantation. We performed immunoblotting with LTBP-1 on nonreducing an SDS-PAGE blot of crude plasma membrane proteins from stages of embryo implantation. Anti-LTBP-1-detected LLC was observed high in its expression in the ECM and plasma membrane compartment in all stages of the implantation period. Collectively, this information confirmed that TGF-B1, LAP, and LTBP-1 are the components of LLC in the uterine ECM and plasma membrane compartment.
The crucial role of TGF-B1 signaling in the uterus during embryo implantation has already been reported [61, 62] . We observed that processing of TGF-B1 latent complexes gave rise to a biologically active form of TGF-B1 during embryo implantation. To look into the importance of processing of latent TGF-B1 complex in embryo implantation, we utilized a lysosomotropic drug, i.e., hydroxychloroquine, which is an inhibitor of pro-TGF-B1 processing [54] . The administration of hydroxychloroquine at the Day 4 (1000 h) stage reduced the number of blastocysts at Day 5 (1000 h), decreasing the pregnancy rate at Day 13. This strongly demonstrates that TGF-B1 activation or liberation is important in the process of embryo implantation. Furthermore, FIG. 9 . Effect of pro-TGF-B1 liberation inhibitor hydroxychloroquine on decidualization at Day 7. A and B) Histopathology using hematoxylin and eosin was performed on uterine tissue from implantation and nonimplantation sites of the sham-treated group from Day 7. C) Hydroxychloroquine-treated uterine tissue from Day 7 was stained with hematoxylin and eosin for histological analysis. Em, location of the embryo; LE, luminal epithelium; G, glands; S, stroma; M, myometrium.
LIBERATION OF TGF-B1 FROM LATENT COMPLEX IN UTERUS
we found that hydroxychloroquine delivery in the uterus hindered blastocyst development, which suggests that the TGF-B1 activation process is required during embryo development as well. This could be because of inhibition of embryonic TGF-B1 [63] , but the effect exerted by the pro-TGF-B1 processinginhibitor drugs on embryonic TGF-B1 cannot be answered by this study. However, our study clearly suggests the involvement of maternal TGF-B1 in embryo implantation.
Further, we verified liberation of the maternal (uterine) biologically active TGF-B1 form at Day 5 (1000 h) in the presence of the pro-TGF-B processing inhibitor hydroxychloroquine. The hydroxychloroquine-treated group exhibited blockage of biologically active TGF-B1 in the uterus at Day 5 (1000 h). The level of SMAD3 and pSMAD3 was found to recede upon hydroxychloroquine treatment. This domain of study suggests that the biologically active TGF-B1 can trigger SMAD3 signaling in the uterus, which is crucial for embryo implantation.
The TGF-B1 produced by the endometrial epithelial cells acts on the stromal cells to enhance the decidualization [9] . Though the TGF-B1 participates in various types of decidualization-related signaling, its own regulation is poorly understood. Classically, TGF-B1 regulation is reported to be at the gene-expression level in the uterus [60] . Additionally, the TGF-B1 can also be regulated via its release to active form from the latent complex [14] . Therefore, we determined that the liberation of TGF-B1 from its latent inactive complex is another regulatory mechanism that may be referred to as a posttranslational regulatory mechanism. The biologically active form of TGF-B1 was enhanced remarkably in the decidualized uterus. In addition to this, we observed enhanced SLC in the decidualized uterine group, which suggests availability of SLC for the active TGF-B1 liberation. The SMAD3 is a signal transducer of TGF-B1 and is required during decidualization in the uterus [59] . We found a high level of phosphorylated SMAD3 in the decidualized uterus, which correlates positively with liberation of a high level TGF-B1. This confirms liberation of biologically active TGF-B1 in the uterus during embryo implantation. The inhibition of maternal (uterine) latent TGF-B1 processing at the preimplantation stage of the implantation period can affect pregnancy in a negative manner. Further, we have seen impaired development of the blastocyst during the postimplantation stages, where the decidualization is initiated. Moreover, the uterine tissue growth was reduced in the hydroxychloroquine group during the decidualization stage, Day 7 of pregnancy, in comparison to the sham treatment, where the reaction decidualization is reported [64] . The lumen was wide open, rather than the required closure for the embryo implantation process. This could possibly be explained by the inhibition of biologically active TGF-B1, which in turn compromised the process of decidualization. Thus, the liberation of biologically active TGF-B1 from its latent complex in the uterus seems to be important for embryo implantation.
Progesterone can induce TGF-B1 secretion from epithelial cells in the uterus in vitro [9] , but the in vivo condition remains obscure. However, we found recruitment of biologically active TGF-B1 on the uterine plasma membrane during the window of embryo implantation, which is under the strict control of an estradiol surge. We utilized a delayed-implantation mouse model, which is similar enough to a human pregnancy model to study the role of ovarian steroids, i.e., progesterone and estradiol, in the uterine TGF-B1 activation process. Based on this study, we found that progesterone induced expression of 
TGF-B1, but could not release an optimum level of active TGF-B1. However, supplementation of estradiol on Day 7 enhanced the release of TGF-B1 into a biologically active form, i.e., the monomer. This implies requirement of estrogen for functional activation or release of TGF-B1 from its latent complex. The LAP was also present on the both the progesterone alone and the progesterone þ estradiol combination, describing LLC and SLC. This points to a role of estradiol in regulation of liberation of biologically active TGF-B1 from its latent complex in the plasma membrane of the mouse uterus.
Our observation provides a definite answer to TGF-B1 liberation-dependent embryo implantation. Release of biologically active TGF-B1 at the implantation sites of the periimplantation stage might establish the maximum receptivity of the uterus for embryo implantation, as inhibition of active TGF-B1 release reduced the development of implantation sites. It may be speculated that administration of the pro-TGF-B1 processing inhibitor hydroxychloroquine might have resulted in a decrease in uterine TGF-B1 activation, which led to a lack of concordant interaction between an invading embryo and the receptive/nidatory endometrium.
In conclusion, this study provides detailed information about the mechanism of active TGF-B1 liberation from its latent complex during embryo implantation and decidualization in the mouse uterus (Fig. 11) . The uterine ECM subcellular compartment also expresses LLC and SLC, which might serve as a reservoir of TGF-B1. The peri-implantation/Day 5 (0500 h) stage of the implantation period consists of a highly active TGF-B1 isoform (;17-kDa monomer) on the uterine plasma membrane, which is restricted to the implantation sites. Most importantly, this study demonstrates for the first time the essential role of TGF-B1 activation from the latent TGF-B1 complex in the embryo implantation process. Estrogen is a key player in regulating the bioavailability of active TGF-B1 in the uterus that is receptive for embryo implantation (Fig. 11) . Furthermore, our study strongly suggests that the TGF-B1 liberation/activation process is necessary during the implantation period to establish pregnancy.
